Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to compare the effects of fasting and fed conditions with repeat doses of GSK256073F in HVT subjects.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00808093
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 1
Start date May 12, 2008
Completion date August 27, 2008

See also
  Status Clinical Trial Phase
Completed NCT00783549 - A Study in Healthy Volunteers of Single Doses of Orally Administered Investigational Product to Investigate Safety, Tolerability, and Pharmacokinecs. Phase 1
Completed NCT01218204 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Administering Multiple Oral Doses of GSK1292263 Alone and With Atorvastatin Phase 2
Completed NCT00551694 - A Second Study to Determine the Effect of GSK256073A on HVTs Phase 1
Completed NCT00169559 - Dyslipidemia Study Investigating The Increase In "Good Cholesterol" Phase 2
Completed NCT00488449 - Study Of Pharmacokinetics and Pharmacodynamics Effects Of GSK256073A On Healthy Volunteers Phase 1
Completed NCT00903617 - Study to Test GSK256073 in Patients With Dyslipidemia Phase 2
Completed NCT00474864 - Study To Evaluate The Effects Of GW856553 On Endothelial Function/Vascular Compliance In Subjects With Dyslipidaemia. Phase 2
Completed NCT00608699 - A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers Phase 1
Terminated NCT00318617 - Effect Of GW501516X On How The Heart Obtains And Uses Energy N/A
Completed NCT00388180 - An Exploratory Study To Look At The Effect Of Two Investigational Drugs On Body Fat And Inflammation N/A
Completed NCT00158899 - GW501516 In Subjects Who Have Low Level Of High-Density Lipoprotein Cholesterol Phase 2